Skip to content
Search

Latest Stories

Infosys forecasts revenue slowdown on uncertain outlook

The company, like local rival TCS, also gained from the increased use of digital services during the Covid pandemic

Infosys forecasts revenue slowdown on uncertain outlook

Indian software giant Infosys reported a lower-than-expected profit rise for the March quarter on Thursday (13) and flagged softer revenue guidance on the back of global economic and financial uncertainty.

Infosys, India's second-largest information technology firm, benefitted from an IT boom that made India the back office to the world for subcontracted work.

The company, like local rival TCS, also gained from the increased use of digital services during the Covid pandemic.

But continued economic uncertainty and financial sector turmoil have made some clients, particularly in Western markets, tighten their belts.

Net profit came in at Rs 61.3 billion ($748 million) for the March quarter, a 7.8 per cent rise from the same period last year.

Revenue grew 8.8 per cent year-on-year, but fell 3.2 per cent quarter-on-quarter in constant currency terms, reflecting the challenging market conditions.

The Bengaluru-headquartered firm forecast revenue growth of four to seven per cent in constant currency terms for the year to March 2024, lower than analysts' expectations.

"During the quarter we saw unplanned project rampdowns in some of our clients and delays in decision-making, which resulted in lower volumes," Infosys chief executive Salil Parekh said in a media briefing.

"While we saw some signs of stabilisation in March, the environment remains uncertain," he said.

Infosys earns more than 85 per cent of its revenue from North American and European markets.

Employee attrition, an important metric for software companies in India's competitive IT market, slipped to 20.9 per cent compared with 24.3 per cent for the December quarter.

But the total number of Infosys employees fell by more than 3,600.

Rival IT giant TCS reported on Wednesday (12) a weaker-than-expected increase in net profit for the first three months of the year, as the fallout from the economic uncertainty and banking turmoil weighed on its US operations.

Shares in Infosys closed nearly 2.8 per cent lower in Mumbai trading ahead of the earnings announcement.

(AFP)

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less